Search terms
Results 1 - 9 of 9 - ordered by :

Sweden is unique among countries in having comprehensive and high-quality cardiovascular registry data, says Prof. Omerovic, allowing a relatively large number of patients to be investigated over a ...

Date : 28/05/2019

Findings from the PARADIGM-HF trial, published simultaneously in the New England Journal of Medicine, ? are extraordinarily powerful and compelling; they are destined to change the management of ...

Date : 30/08/2014

The latest study, published today in the European Journal of Heart Failure, also found that heart failure patients whose ejection fraction is not reduced (i.e., is “preserved”) have a ...

Date : 08/03/2012

Beta blockers reduce mortality risk by 20% over 5 years in heart failure patients with atrial fibrillation in a real-life setting, Danish researchers have discovered in findings that contradict those ...

Date : 21/05/2016

The Congress is the main annual meeting of the Heart Failure Association of the European Society of Cardiology. Professor Bertram Pitt said: “We’ve had many studies showing that ACE ...

Date : 18/05/2014

Sleeping pills increase the risk of cardiovascular events in heart failure patients by 8-fold, according to research from Japan. The researchers retrospectively examined the medical records of 111 ...

Date : 17/05/2014

EMBARGO : 1 Septembre 2015 at 08:00 BST The Hot Line study, presented at ESC Congress 2015, and published simultaneously in the New England Journal of Medicine, “provides practice-changing ...

Date : 01/09/2015

Over a median follow-up of 18.2 months, the primary outcome occurred in 386 of 2,373 patients (16.3%) in the dapagliflozin group and in 502 of 2,371 patients (21.2%) in the placebo group (hazard ...

Date : 01/09/2019

The risk of death is highest in the first 6 months following myocardial infarction (MI).1,2 However, current ESC Guidelines recommend a delay of at least 6 weeks after MI before considering ...

Date : 04/09/2019